Results 181 to 190 of about 22,494 (197)

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate

Nature Medicine, 2006
Risto Kerkelä, Anthony Rosenzweig, Richard A Van Etten   +2 more
exaly  

Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial

Lancet Oncology, The, 2012
Grzegorz Nalepa, Daniel C Bowers, Terry A Vik   +2 more
exaly  

Response to Imatinib Mesylate in Patients with Chronic Myeloproliferative Diseases with Rearrangements of the Platelet-Derived Growth Factor Receptor Beta

New England Journal of Medicine, 2002
Jane F Apperley, Barbara J Bain, Andrew Chase   +2 more
exaly  

Imatinib Mesylate — Uncovering a Fast Track to Adaptive Immunity

New England Journal of Medicine, 2006
Mark J Smyth
exaly  

Effective Targeting of Quiescent Chronic Myelogenous Leukemia Stem Cells by Histone Deacetylase Inhibitors in Combination with Imatinib Mesylate

Cancer Cell, 2010
Leonard D Shultz, Ravi Bhatia
exaly  

Solubility measurement of a chemotherapeutic agent (Imatinib mesylate) in supercritical carbon dioxide: Assessment of new empirical model

Journal of Supercritical Fluids, 2019
Gholamhossein Sodeifian, Fariba Razmimanesh, Seyed Ali Sajadian   +2 more
exaly  

Hypopigmentation from Imatinib Mesylate (Gleevec)

Journal of Pediatric Hematology/Oncology, 2004
William J, Grossman, David B, Wilson
openaire   +2 more sources

Dysregulation of bone remodeling by imatinib mesylate

Blood, 2010
Kate Vandyke, Stephen Fitter, Andrew W C Zannettino   +2 more
exaly  

Imatinib Mesylate for Cerebral Langerhans'-Cell Histiocytosis

New England Journal of Medicine, 2004
Liliana Montella, Giovannella Palmieri
exaly  

Another Look at Imatinib Mesylate

New England Journal of Medicine, 2007
Schellings, Mark W., Löwenberg, Bob, Pinto, Yigal M.   +2 more
openaire   +3 more sources